Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · RECURSION PHARMACEUTICALS, INC. (RXRX)

Recursion prices $200 million stock offering at $3.25 a share alongside REC-4881 data

Mixed Impact 4 of 5 financing Written later

Recursion agreed to sell 61,540,000 new Class A common shares at $3.25 each, for expected gross proceeds of about $200 million, with closing expected October 16, 2026. The company also reported preliminary cash of about $561 million as of September 30, 2026, which it says will fund operations into 2029, and released updated Phase 1b/2 data for REC-4881 and news of a Sanofi option on a development candidate.

Key points

  • Offering of 61,540,000 Class A shares at $3.25 per share, with expected gross proceeds of about $200 million before fees and expenses, closing expected October 16, 2026
  • Executive officers and directors agreed to a 45-day lock-up on sales of company securities, subject to exceptions
  • Preliminary cash, cash equivalents and restricted cash of about $561 million as of September 30, 2026; company expects funding into 2029
  • Sanofi optioned a development candidate, triggering a $10 million milestone payment and bringing total collaboration payments to $144 million

The filing

CompanyRECURSION PHARMACEUTICALS, INC. (RXRX)
Form8-K, current report
Filed with the SECOct 15, 2026, 8:46 AM ET
Accession number0001601830-26-000128

Items reported: 1.01 Material Definitive Agreement2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 15, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.